IBS-Related Changes in Realtime

Sympathetic nervous system, involved in pathogenesis, active pre- and post-defecation

Translate to Spanish or other 102 languages!

Heart rate variability was measured using a wearable device, a sleeveless shirt with a transmitter. Heart rate variability was recorded on a smartphone using Bluetooth, while activities such as bowel movements and sleeping were tracked using an independently developed smartphone application. Credit: Fumio Tanaka, Osaka Metropolitan University
Heart rate variability was measured using a wearable device, a sleeveless shirt with a transmitter. Heart rate variability was recorded on a smartphone using Bluetooth, while activities such as bowel movements and sleeping were tracked using an independently developed smartphone application. Image Credit: Fumio Tanaka, Osaka Metropolitan University

Mega Doctor News

- Advertisement -

 by Osaka Metropolitan University

Newswise — Irritable bowel syndrome (IBS) is a difficult disease to treat, characterized by chronic abdominal pain related to bowel movements, of which there are four types: diarrheal, constipation, mixed, and unclassifiable. Patients with IBS report a reduction in quality of life and experiences of social discomfort, as they are forced to restrict their activity, such as work or travel, because of the sudden and unpredictable need to use the bathroom. While there have been studies of IBS-related abnormalities in the autonomic nervous system based on 24-hour electrocardiogram measurement, until now none of them examined changes in the autonomic nervous system during bowel movements.

Associate Professor Fumio Tanaka and his research group at the Osaka Metropolitan University Graduate School of Medicine recorded the autonomic nervous system activity of IBS patients and healthy subjects using a wearable device and tracked activities such as defecation and sleep. As a result, they found that unlike healthy subjects, the sympathetic nervous system of IBS patients was activated 2 minutes before defecation and persisted until 9 minutes after defecation. Furthermore, the activation of the sympathetic nervous system was found to be associated with greater abdominal pain and lower quality of life. The research results were published online in PLOS ONE on December 9, 2022.

- Advertisement -

“This research is characterized by the fact that autonomic nervous system functions are measured using a clothing-type wearable device, and that lifestyle events such as defecation and abdominal symptoms are input simultaneously in real time, using a smartphone application originally developed by our group. As a result, autonomic nervous system activity during defecation was accurately evaluated. We hope that further research will improve the quality of life of IBS patients and help elucidate the pathophysiology,” Professor Tanaka concluded.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

DHR Health Recertified for Advanced Hip & Knee Replacements

DHR Health has once again earned The Joint Commission's Advanced Certification in Total Hip and Total Knee Replacement, reaffirming its commitment to providing high-quality, patient-centered orthopedic care to the Rio Grande Valley.

Study Points to High Blood Pressure as a Key Factor in Rising Heart Disease Rates

Heart disease is the leading cause of death in the United States according to the Journal of the American College of Cardiology. Its impact extends beyond biology, with social detriments such as food insecurity, socioeconomic status and education influencing outcomes.

Dysfunctional, Not Missing, Immune Cells Explain Skin Cancer Risk in Immunosuppressed Patients

Researchers at The University of Texas MD Anderson Cancer Center have discovered that immunosuppressed patients with non-melanoma skin cancer are not missing the key cancer-fighting immune cells found in immunocompetent patients, but those cells – known as macrophages – have lost the ability to communicate effectively.

New Study Reveals Real-World Safety Findings for Latest Alzheimer’s Treatment

As new Alzheimer’s drugs move from clinical trials into everyday care, families are asking whether these treatments are safe, how long patients can stay on them, and whether they truly slow the disease outside tightly controlled studies.
- Advertisement -